Evaluation of prognostic factors and survival results in pancreatic carcinomas in Turkey

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6573-6578

  Canyilmaz, Emine ^a   Serdar, Lasif ^a   Uslu, Gonca Hanedan ^b   Soydemir, Gulsen ^a   Bahat, Zumrut ^a   Yoney, Adnan ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b Kanuni Research and Education Hospital ^*  (Turkey)

Author keywords

CEA; Chemotherapy; Pancreatic cancer; Radiotherapy

Indexed keywords

EID: 84892463341     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6573     Document Type: Article

References (33)

1. Bayraktar S, Bayraktar UD, Rocha-Lima CM (2010). Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol, 16, 673-82.
2. Bernhard J, Dietrich D, Glimelius B, et al (2010). Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer, 103, 1318-24.
3. Boeck S, Hinke A, Wilkowsky R, et al (2007). Heinemann V. Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol, 13, 224-7.
4. Bramhall SR, Allum WH, Jones AG, et al (1995). Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg, 82, 111-5.
5. Brennan MF, Kattan M, Klimstra D, et al (2004). Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg, 240, 293-8.
6. Burris HA, Moore MJ, Andersen J, et al (1997). Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 15, 2403-13.
7. Conlon KC, Klimstra DS, Brennan MF (1996). Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg, 223, 273-9.
8. Evans D, Abbruzzese J, Willett C (2001). Cancer of the pancreas, 6th ed. Philadelphia: Lippincott Williams and Wilkins
9. Foo ML, Gunderson LL, Nagorney DM, et al (1993). Paterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorourasil. Int J Radiat Oncol Biol Phys, 26, 483-9.
10. Garcea G, Dennison AR, Pattenden CJ, et al (2008): Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP, 9, 99-132.
11. Gudjonsson B (1995). Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg, 181, 483-503.
12. Gastrointestinal Tumor Study Group (1985). Radiation therapy combined with Adriamycin or 5-fluorourasil for the treatment of locally unresectable pancreatic carcinoma. Cancer, 56, 2563-8.
13. Gastrointestinal Tumor Study Group (1979). A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann Surg, 189, 205-8.
14. Heinemann V, Boeck S, Hinke A, et al (2008). Meta-analysis of randomized trials: evaluation of benefit from gemcitabinebased combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer, 8, 82
15. Huguet F, Andre T, Hammel P, et al (2007). Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol, 25, 326-31.
16. Iacobuzio-Donahue CA, Fu B, et al (2009). DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol, 27, 1806-13.
17. Ishii H, Okada S, Nose H, et al (1996). Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas, 12, 267-71.
18. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49
19. Klaassen DJ, Maclntyre JM, Catton GE, et al (1985). Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorourasil alone with radiation plus concurrent and maintenance 5-fluorourasil- an Eastern Cooperative Oncology Group study. J Clin Oncol, 3, 373-8.
20. Kindler HL, Niedzwiecki D, Sutherland S, et al (2010). Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol, 28, 3617-22.
21. Krishnan S, Rana V, Janjan NA, et al (2006). Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 107, 2589-96.
22. Lim JE, Chien MW, Earle CC (2003). Prognostic factors following curative resection for pancreatic adenocarcinoma: a population based, linked database analysis of 396 patients. Ann Surg, 237, 74-85.
23. Malik NK, May KS, Chandrasekhar R, et al (2012). Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol, 3, 326-34.
24. Moertel CG, Childs DS Jr, Reitemeier RJ, et al (1969). Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet, 2, 865-7.
25. Mullinax JE, Hernandez JM, Toomey P, et al (2012). Survival after pancreatectomy for pancreatic adenocarcinoma is not impacted by performance status. Am J Surg, 204, 704-8.
26. Neoptolemos JP, Stocken DD, Friess H, et al (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med, 350, 1200-10.
27. Ozaki H (1992). Improvement of pancreatic cancer treatment from the Japanese experience in the 1980s. Int J Pancreatol, 12, 5-9.
28. Philip A, Mooney M, Jaffe D, et al (2009). Consensus report of the National Cancer Institute Clinical Trials Planning Meeting on pancreas cancer treatment. J Clin Oncol, 27, 5660-9.
29. Sultana A, Tudur Smith C, Cunningham D, et al (2007). Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer, 96, 1183-90.
30. Vainshtein JM, Schipper M, Zalupski MM, et al (2012). Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study. Int J Radiat Oncol Biol Phys, 86, 96-101
31. Winter JM, Yeo CJ, Brody JR (2013). Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol, 7, 15-22.
32. Yeo CJ, Yeo TP, Hruban RH, et al (2005). Cancer of the Pancreas. In: Devita, Vincent T.; Hellman, Samuel; Rosenberg, Steven A. Cancer: Principles and Practice of Oncology, 7th Edition, Lippincott Williams and Wilkins, 947-50 (Beyza-15).
33. Yovino S, Maidment BW 3rd, Herman JM, et al (2012). Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys, 83, 916-20.